Immunotherapy for ocular inflammatory disease

  • Kathrin H. Greiner
  • John V. Forrester


Uveitis has been defined as inflammation of the uveal tract (iris, ciliary body, or choroid).More recently it has been recharacterised as intraocular inflammation (IOI) since many forms of uveitis involve intraocular structures such as the retina,vitreous, and even the lens(Forrester et al. 1998).


Mycophenolate Mofetil Intraocular Inflammation Posterior Uveitis Experimental Model Autoimmune Uveoretinitis Ocular Inflammatory Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Broderick C, Duncan L, Taylor N, Dick AD (2000) IFN-gamma and LPS-mediated IL-10-dependent suppression of retinal microglial activation. Invest Ophthalmol Vis Sci 41: 2613–2622PubMedGoogle Scholar
  2. Caspi RR, Grubbs BG, Chan CC, Chader GJ, Wiggert B (1992) Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. J Immunol 148: 2384–2389PubMedGoogle Scholar
  3. Dev S, McCallum RM, Jaffe GJ (1999) Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 106: 111–118PubMedCrossRefGoogle Scholar
  4. Dick AD, Cheng YF, Liversidge J, Forrester JY (1994) Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis. Immunology 82: 625–631PubMedGoogle Scholar
  5. Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, Sedgwick JD (1996) Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 26: 1018–1025PubMedCrossRefGoogle Scholar
  6. Dick AD, Kreutzer B, Laliotou B, Forrester JV (1998) Effects of mycophenolate mofetil on nasal mucosal tolerance induction. Invest Ophthalmol Vis Sci 39: 835–840PubMedGoogle Scholar
  7. Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, Isaacs JD (2000) Campath-IH therapy in refractory ocular inflammatory disease. Br J Ophthalmol 84: 107–109PubMedCrossRefGoogle Scholar
  8. Feltkamp TEW, BreurVriesendorp BS, Derhaag PJFM (1994) HLA-B27 subtypes and acute anterior uveitis: a review. Reg Immunol 6: 8–11Google Scholar
  9. Forrester JY (1990) Uveitis. Br J Ophthalmol 74: 620–622PubMedCrossRefGoogle Scholar
  10. Forrester JV (1991) Uveitis: pathogenesis. Lancet 338(8781): 1498–1501PubMedCrossRefGoogle Scholar
  11. Forrester JV (1992) Duke-Elder Lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye 6 (Pt 5): 433–446PubMedCrossRefGoogle Scholar
  12. Forrester JV, Liversidge J, Dua HS (1990a) Regulation of the local immune response by retinal cells. Curr Eye Res 9 Suppl: 183–191CrossRefGoogle Scholar
  13. Forrester JV, Liversidge JM, Dua HS, Towler HM, McMenamin PG (1990b) Comparison of clinical and experimental uveitis. Curr Eye Res 9 Suppl: 75–84CrossRefGoogle Scholar
  14. Forrester JV, Okada AA, Benezra D, Ohno S (1998a). In: Forrester JV, Okada AA, BenEzra D, Ohno S (eds) Posterior segment intraocular inflammation: guidelines. Kugler Publications, The Hague, The Netherlands, pp 3–7Google Scholar
  15. Forrester JV, Huitinga I, Lumsden L, Dijkstra CD (1998b) Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res 17: 426–437CrossRefGoogle Scholar
  16. Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Volcker HE (1992) Low-dose methotrexate treatment in non-infectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1: 142–144PubMedGoogle Scholar
  17. Hunger RE, Carnaud C, Garcia I, Vassalli P, Mueller C (1997) Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 27: 255–261PubMedCrossRefGoogle Scholar
  18. Isaacs JD, Hale G, Waldmann H, Dick AD, Haynes R, Forrester JV, Watson P, Meyer PA (1995) Monoclonal antibody therapy of chronic intraocular inflammation using campath-lH. Br J Ophthalmol 79: 1054–1055PubMedCrossRefGoogle Scholar
  19. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130: 492–513PubMedCrossRefGoogle Scholar
  20. Jaffe GJ, Yang CS, Want XC, Cousins SW, Gallemore RP, Ashton P (1998) Intravitreal sustained-release cyclosporin in the treatment of experimental uveitis. Ophthalmology 105: 46PubMedCrossRefGoogle Scholar
  21. Jiang HR, Taylor N, Duncan L, Dick AD, Forrester JV (2001) Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction. Br J Ophthalmol 85: 739–744PubMedCrossRefGoogle Scholar
  22. Khanna AK, Cairns VR, Becker CG, Hosenpud JD (1999) Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 67: 882–889PubMedCrossRefGoogle Scholar
  23. Kilmartin DJ, Forrester JV, Dick AD (1998) Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 352: 35–36PubMedCrossRefGoogle Scholar
  24. Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD (2001) CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci 42: 1285–1292PubMedGoogle Scholar
  25. Kreutzer B, Laliotou B, Cheng YF, Liversidge J, Forrester JV, Dick AD (1997) Nasal administration of retinal antigens maintains immunosuppression of uveoretinitis in cyclosporin-A-treated Lewis rats: future treatment of endogenous posterior uveoretinitis? Eye 11 (Pt 4): 445–452PubMedCrossRefGoogle Scholar
  26. Larkin G, Lightman S (1999) Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology 106: 370–374PubMedCrossRefGoogle Scholar
  27. Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, Elliott J, Waldmann H (1996) Treatment of refractory Wegeners granulomatosis with humanised monoclonal antibodies. Q J Med 89: 903–912CrossRefGoogle Scholar
  28. Matsubara T, Pararajasegaram G, Wu GS, Rao NA (1999) Retinal microglia differentially express pheno-typic markers of antigen-presenting cells in vitro. Invest Ophthalmol Vis Sci 40: 3186–3193PubMedGoogle Scholar
  29. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141–147PubMedCrossRefGoogle Scholar
  30. Newman DK, Isaacs JD, Watson PG, Meyer PA, Hale G, Waldmann H (1995) Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, Campath-IH. Eye 9: 564–569PubMedCrossRefGoogle Scholar
  31. Nussenblatt RB, Whitcup SM, de Smet MD, Caspi RR, Kozhich AT, Weiner HL, Vistica B, Gery I (1996) Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann N Y Acad Sci 778: 325–337PubMedCrossRefGoogle Scholar
  32. Nussenblatt RB, Gery I, Weiner HL, Ferris FL, Shiloach J, Remaley N, Perry C, Caspi RR, Hafler DA, Foster CS, Whitcup SM (1997) Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 123: 583–592PubMedGoogle Scholar
  33. Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P, Sran P, Yaffe A, Goldman CK, Waldmann TA, Whitcup SM (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 96: 7462–7466PubMedCrossRefGoogle Scholar
  34. Provis JM, Diaz CM, Penfold PL (1996) Microglia in human retina: a heterogeneous population with distinct ontogenies. Perspect Dev Neurobiol 3: 213–222PubMedGoogle Scholar
  35. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44: 1411–1415PubMedCrossRefGoogle Scholar
  36. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 358(9278): 295–296PubMedCrossRefGoogle Scholar
  37. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM (1992) Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99: 1419–1423PubMedGoogle Scholar
  38. Shi FD, Li H, Wang H, Bai X, van der Meide PH, Link H, Ljunggren HG (1999) Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol 162: 5757–5763PubMedGoogle Scholar
  39. Smith JR, Hart PH, Parish CR, Standfield SD, Coster DJ, Williams KA (1999) Experimental melanin-induced uveitis in the Fischer 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate. Clin Exp Immunol 115: 64–71PubMedCrossRefGoogle Scholar
  40. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45: 252–257PubMedCrossRefGoogle Scholar
  41. Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13: 151–153PubMedCrossRefGoogle Scholar
  42. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, Tolman DE, Frazier OH, Young JB, Van Veldhuisen P (1999) A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18: 336–345CrossRefGoogle Scholar
  43. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89: 4845–4849PubMedCrossRefGoogle Scholar
  44. Wallace CA (1998) The use of methotrexate in childhood rheumatic disease. Arthritis Rheum 41: 381–391PubMedCrossRefGoogle Scholar
  45. Wang Y, Calder VL, Lightman SL, Greenwood J (1995) Antigen presentation by rat brain and retinal endothelial cells. J Neuroimmunol 61: 231–239PubMedCrossRefGoogle Scholar
  46. Xiao BG, Link H (1997) Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 85: 119–128PubMedCrossRefGoogle Scholar
  47. Yang P, Das PK, Kijlstra A (2000) Localization and characterization of immunocompetent cells in the human retina. Ocul Immunol Inflamm 8: 149–157PubMedGoogle Scholar
  48. Zhang J, Wu GS, Ishimoto S, Pararajasegaram G, Rao NA (1997) Expression of major histocompatibility complex molecules in rodent retina: immunohistochemical study. Invest Ophthalmol Vis Sci 38: 1848–1857PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Kathrin H. Greiner
    • 1
  • John V. Forrester
    • 1
  1. 1.Department of OphthalmologyMedical School, Aberdeen Royal InfirmaryAberdeenUK

Personalised recommendations